About Srinivas Akkaraju
Srinivas Akkaraju is a director at Alumis.
Srinivas Akkaraju reports to the SEC as a director or major shareholder of 30 public companies, including vTv Therapeutics (VTVT), Scholar Rock Holding (SRRK) and Kalaris Therapeutics (KLRS).
Srinivas Akkaraju first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Srinivas Akkaraju in the role, so the role may have started earlier or lasted longer.
VI
vTv Therapeutics Inc.
Director and 10% owner
2024 – 2026 · Public company (VTVT)
SC
Scholar Rock Holding Corp
Director and 10% owner
2022 – 2026 · Public company (SRRK)
KI
Kalaris Therapeutics, Inc.
Director and 10% owner
2025 – 2026 · Public company (KLRS)
MI
Mineralys Therapeutics, Inc.
Director and 10% owner
2023 – 2026 · Public company (MLYS)
NI
Neurogene Inc.
10% owner
2024 · Public company (NGNE)
SI
Syros Pharmaceuticals, Inc.
Director
2017 – 2024 · Public company (SYRS)
CI
II
Intercept Pharmaceuticals, Inc.
Director
2012 – 2023 · Public company (ICPT)
CI
Chinook Therapeutics, Inc.
Director
2020 – 2023 · Public company (KDNY)
JC
Jiya Acquisition Corp.
Director and 10% owner
2020 – 2022 · Public company (JYAC)
LI
LENZ Therapeutics, Inc.
10% owner
2021 – 2022 · Public company (LENZ)
SI
Seagen Inc.
Director
2006 – 2020 · Public company (SGEN)
AI
Aravive, Inc.
Director and 10% owner
2014 – 2020 · Public company (ARAV)
PI
Principia Biopharma Inc.
Director
2018 – 2019 · Public company (PRNB)
AI
aTYR PHARMA INC
Director and 10% owner
2015 – 2017 · Public company (ATYR)
ZI
ZS Pharma, Inc.
Director
2014 – 2015 · Public company (ZSPH)
AI
Aclaris Therapeutics, Inc.
10% owner
2015 · Public company (ACRS)
SI
Synlogic, Inc.
10% owner
2015 · Public company (SYBX)
SI
Spark Therapeutics, Inc.
10% owner
2015 · Public company (ONCE)
OI
Ocugen, Inc.
10% owner
2014 · Public company (OCGN)
AI
Alimera Sciences Inc.
10% owner
2014 · Public company (ALIM)
LI
Lite Strategy, Inc.
10% owner
2012 – 2013 · Public company (LITS)
WC
World Heart Corp.
10% owner
2010 – 2012 · Public company (WHRT)
DI
Durata Therapeutics, Inc.
10% owner
2012 · Public company (DRTX)
SC
Synageva Biopharma Corp.
Director
2011 – 2012 · Public company (GEVA)
II
Icagen Inc.
Reporting person
2011 · Public company (ICGN)
PI
Paratek Pharmaceuticals, Inc.
10% owner
2009 – 2011 · Public company (PRTK)
PC
Pharmos Corp.
Director
2006 – 2011 · Public company (PARS.PK)
BI
Barrier Therapeutics Inc.
Director
2007 – 2008 · Public company (BTRX)
Key Colleagues at Startups
The people Srinivas Akkaraju works with at each company, as listed on that company's latest Form D.
Alumis Inc. · Form D, Jul 24, 2024
JS
John Schroer
Executive officer
JT
James Tananbaum
Director
DR
Derrick Richardson
Executive officer
PM
Patrick Machado
Director
SS
Sapna Srivastava
Director
MB
Martin Babler
CEO and director
MB
Mark Bradley
Executive officer
ZY
Zhengbin Yao
Director
SK
Sara Klein
Executive officer
DG
David Goldstein
Executive officer
JD
Jorn Drappa
Executive officer
AC
Alan Colowick
Director
RH
Roy Hardiman
Executive officer